Information Provided By: 
Fly News Breaks for October 23, 2019
ETON
Oct 23, 2019 | 07:09 EDT
H.C. Wainwright analyst Raghuram Selvaraju raised his price target for Eton Pharmaceuticals to $21 from $18 after the company reported that its intravenous phenylephrine injection product, Biorphen, had been approved by the FDA. This is a key milestone for Eton, says the analyst, who continues to expect Biorphen to deliver "considerable" long-term topline growth, with peak sales in the U.S. of over $250M attainable by 2030. Selvaraju keeps a Buy rating on the shares.
News For ETON From the Last 2 Days
There are no results for your query ETON
